Similar articles

• [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Combinations of conventional disease-modifying antirheumatic agents].

  Schnabel A, Gross WL. Schnabel A, et al. Dtsch Med Wochenschr. 2003 Jan 24;128(4):147-9. doi: 10.1055/s-2003-36869. Dtsch Med Wochenschr. 2003. PMID: 12589584 German. No abstract available.
• [Three joints swollen, blood sedimentation increased. Methotrexate to be given immediately?].

  Burmester GR. Burmester GR. MMW Fortschr Med. 2004 Sep 9;146(37):10. MMW Fortschr Med. 2004. PMID: 15887693 German. No abstract available.
• Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.

  Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Leirisalo-Repo M. Puolakka K, et al. Arthritis Rheum. 2004 Jan;50(1):55-62. doi: 10.1002/art.11436. Arthritis Rheum. 2004. PMID: 14730599 Clinical Trial.
• The BeSt story: on strategy trials in rheumatoid arthritis.

  Klarenbeek NB, Allaart CF, Kerstens PJ, Huizinga TW, Dijkmans BA. Klarenbeek NB, et al. Curr Opin Rheumatol. 2009 May;21(3):291-8. doi: 10.1097/BOR.0b013e32832a2f1c. Curr Opin Rheumatol. 2009. PMID: 19318946 Review.
• Lefunomide in combination therapy.

  Kalden JR, Smolen JS, Emery P, van Riel PL, Dougados M, Strand CV, Breedveld FC. Kalden JR, et al. J Rheumatol Suppl. 2004 Jun;71:25-30. J Rheumatol Suppl. 2004. PMID: 15170905 Review.